Inquiry

Histiocytic and Dendritic Cell Neoplasms

In the world of oncology, the study of rare diseases such as histiocytic and dendritic cell neoplasms present unique challenges. At our company, we are dedicated to pushing the boundaries of scientific research and developing innovative therapies to combat these complex diseases.

Overview of Histiocytic and Dendritic Cell Neoplasms

Histiocytic and dendritic cell neoplasms are a group of rare and heterogeneous diseases characterized by the abnormal proliferation and accumulation of histiocytes and dendritic cells. These cells, which play crucial roles in immune responses, become dysregulated, leading to the development of tumors in various tissues. The pathogenesis of histiocytic and dendritic cell neoplasms is multifactorial and not yet fully elucidated. However, it is believed that the transformation of precursor cells, such as monocytes and dendritic cell precursors, contributes to the development of these neoplasms.

Classification of Histiocytic and Dendritic Cell Neoplasms

• Plasmacytoid dendritic cell neoplasms
  • mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
  • blastic plasmacytoid dendritic cell neoplasm

• Langerhans cell and other dendritic cell neoplasms
  • Langerhans cells neoplasms

• other dendritic cell neoplasms

• Histiocyte/macrophage neoplasms
  • juvenile xanthogranuloma
  • Erdheim-Chester disease

  • Rosai-Dorfman Disease
  • ALK-positive histiocytosis

  • histiocytic sarcoma

Potential Targets of Histiocytic and Dendritic Cell Neoplasms

Therapy Development of Histiocytic and Dendritic Cell Neoplasms

Our Services

At our company, we are at the forefront of histiocytic and dendritic cell neoplasm diagnostics and therapy development. Our dedicated team of scientists and researchers works tirelessly to identify novel therapeutic targets and develop innovative drugs to combat these diseases. Our cutting-edge drug development services encompass target identification and validation, hit-to-lead optimization, preclinical pharmacology, toxicology, and pharmacokinetic analysis.

Our Therapy Development Platforms

Furthermore, we provide comprehensive animal model development services, crucial for preclinical studies and the evaluation of potential therapies. By utilizing state-of-the-art technologies and utilizing our extensive expertise, we strive to accelerate the translation of promising therapies from bench to bedside.

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

• Okada, Kanae, et al. "Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t (14; 18) and neoplastic PD‐L1 expression." Pathology International 71.1 (2021): 24-32.
• Pan, Zenggang, and Mina L. Xu. "Histiocytic and dendritic cell neoplasms." Surgical Pathology Clinics 12.3 (2019): 805-829.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Myeloid Proliferations and Neoplasms
• B-cell Lymphoid Proliferations and Lymphomas
• T-cell and NK-cell Lymphoid Proliferations and Lymphomas
• Stroma-derived Neoplasms of Lymphoid Tissues
• Genetic Tumor Syndromes